Thanks for the link, so at 7min 40sec, Dr GK said this Lupin+veyonda study is a phase 2. I recall someone questioning that it is an investigator study so not even considered valid (something like that was said). So in FDA eyes, is it considered phase 2? Just wondering as it would mean Novartis and Noxopharm can technically start phase 3 studies?
A GREAT interview by Peter Switzer, page-2
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |